Archives

by in
Entry Author Date Location
Tapping UCSF Invention, Roche and Versant Dive Into Myelin Repair 06/23/14 San Francisco
RNA Therapeutics Are Here to Stay 06/05/14 San Diego
A Few Raindrops Amid Texas Biotech IPO Drought 05/30/14 Texas
How A Kidney Drug Almost Torpedoed Concert Pharma’s IPO 04/25/14 Boston
Concert Pharma Heads to Nasdaq, Prices IPO at $14 Per Share 02/13/14 Boston
East Coast Biotech Roundup: Genocea, Eleven, NIH/Pharma, & More 02/07/14 Boston
San Diego Life Sciences Roundup: Isis, Receptos, Suneva, and More 01/17/14 San Diego
San Diego Life Sciences Roundup: Receptos, Auspex, Avelas, and More 01/10/14 San Diego
East Coast Biotech Roundup: Scholar Rock, Dicerna, Eleven, & More 01/03/14 Boston
Remembering James L. Vincent, Longtime Biogen Leader 12/31/13 Boston
East Coast Life Sciences Roundup: Sarepta, Agios, Gerngross, & (Much) More 07/26/13 Boston
San Diego Life Sciences Roundup: Illumina, Conatus, Isis, and More 07/25/13 San Diego
Alkermes Adds Cancer, MS Drugs To Growing Portfolio 07/17/13 Boston
Cadence Biomedical Nets $1M, Loads of Press, for Walk-Assist Device 05/30/13 Seattle
Opexa Tries a Personalized Cell Therapy Against Last, Worst Stage of MS 05/02/13 Texas
Acorda Stock Climbs on Post-Stroke Study 04/15/13 New York
Big Data Is BS in Healthcare. When Will It Become Real? 04/15/13 National
San Diego Life Sciences Roundup: Receptos IPO, Isis, Versant, & More 04/12/13 San Diego
East Coast Biotech Roundup: Biogen Idec, Third Rock, T2 Bio, Dart 03/29/13 Boston
Biogen Idec Wins FDA Approval For Oral Multiple Sclerosis Drug 03/27/13 Boston
Allozyne Conducts Round of Employee ‘Furloughs’ 03/15/13 Seattle
San Diego Life Sciences Roundup: Regulus, MEI Pharma, Qualcomm & More 08/16/12 San Diego
Biogen Idec, Regulus Cut Deal to Monitor Multiple Sclerosis 08/15/12 San Diego
Innovimmune Pursues Pharma Partners, Shuns VCs 08/07/12 New York
Genzyme, Epizyme, & Rib-X Among the Week’s Life Sciences Newsmakers 04/27/12 Boston
New Data on Genzyme MS Drug Shows Improvement in Disability 04/24/12 Boston
Five Questions: Acorda CEO Ron Cohen on the Future of Neurology R&D 04/17/12 New York
Provid Pharma Leans on MS Society’s Venture Fund to Boost Lead Drug 04/12/12 New York
How Biogen Idec Overhauled R&D Under Doug Williams 03/07/12 Boston
Transparency Launches as Linux of Drug Development 02/23/12 New York
Page 1 of 6 next page »